LG Chem Is Targeting to Penetrate the Solar Panel Frame Market
19.10.2021 03:00:00 EEST | Business Wire | Press release
LG Chem (KRX: 051910) has developed a plastic material that can replace the metal in solar panel frames for the first time in Korea and starts full-scale market penetration.
LG Chem announced that the Company has developed ‘LUPOY EU5201’, a PC/ASA flame retardant material that maintains the material shape even during temperature changes due to its low thermal expansion levels, using their proprietary technology and manufacturing method.
* PC/ASA: Engineering plastic with enhanced physical properties made by mixing ASA (Acrylonitrile Styrene Acrylate) resins with polycarbonate as a base
Solar panel frames are located at the edge of solar panels to protect and support the panel from external impact. Heat resistance and strong durability against corrosion are required as the materials are exposed outside for a long time, such as on exterior walls or the roof where there is direct sunlight. Solar panel frames account for about 10% of solar panels, and are mainly made of aluminum alloy.
The ‘LUPOY EU5201’, developed by LG Chem, is a high-performance engineering plastic material that supplements the mechanical properties of general plastics by adding glass fiber to polycarbonate compounds.
It has the same level of durability as existing aluminum, but is half the weight and has excellent price competitiveness. Also, it has excellent dimensional stability that maintains its shape even in temperature changes, so it is not easily deteriorated or deformed by the external environment. The chemical decomposition caused by ultraviolet rays exposure has been reduced, which has significantly improved the lifespan of the product compared to general plastics, and the color remains the same even after long-term exposure to ultraviolet rays.
If aluminum is replaced with LG Chem's new engineering plastic material, the weight of the solar panel is expected to decrease dramatically and material cost can also be reduced. This can bring increased convenience during transportation and installation.
LG Chem has PCR PC (Post-Consumer Recycled Polycarbonate) development technology that recycles plastics used by general consumers, so the Company can also produce eco-friendly low-carbon products using high-content PCR raw materials at the request of customers. The Company also plans to review ways to collect the solar panel frame that will be discarded in the future and reproduce them into PCR PC.
LG Chem has secured mass production capability during the first half of this year and started selling products in full-scale in the third quarter. Starting with the supply for solar panel frames, the Company plans to expand the application of materials to interior and exterior materials of automobiles in the future.
Steven Kim, Leader of the Engineering Materials Division at LG Chem, stated, “Solar panel frames made of plastic have many advantages that differentiate them from existing frames, such as ease of installation, and therefore have great market potential. Based on the world's best compounding technology, LG Chem plans to lead the rapidly growing solar material market through continuous R&D and investment into mass production capabilities.”
LG Chem declared ‘carbon-neutral growth by 2050’ last year, the first company to do so in the domestic petrochemical industry, and is promoting RE100, which produces products using renewable energy at all workplaces around the world. LG Chem plans to accelerate carbon-neutral growth through the transition to renewable energy and contribute to the development of renewable energy industry such as solar power through the development of LUPOY EU5201 product.
About LG Chem
LG Chem, Ltd. is Korea’s largest diversified chemical company which operates three main business units: Petrochemicals, Advanced Materials, Life Sciences. The chemical business manufactures a wide range of products, from petrochemical goods to high-value added plastics. It also extends its chemical expertise into high-tech areas such as electronic & battery materials and drugs & vaccines. Throughout multiple production facilities and an extensive distribution network, LG Chem strives to become a leading global company. For more information, please visit the LG Chem website at www.lgchem.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005318/en/
Contact information
LG Chem, Ltd.
Sangkyu Choi, Manager
+82-2-3773-7869
choisg@lgchem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Advances Operational Orchestration Vision with Agentic AI at Kinexions EMEA 202615.9.2026 14:00:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in AI-powered supply chain planning and orchestration, will bring together some of the world’s most innovative supply chain leaders at Kinexions EMEA 2026 from October 26-28. Building on the operational orchestration vision Kinaxis introduced earlier this year, the conference offers an inside look at how leading organizations are harnessing AI innovation and agentic capabilities to help supply chain leaders make better decisions, coordinate action across the business and drive measurable outcomes. From AI Potential to Operational Impact As organizations continue to invest heavily in AI, many struggle to translate intelligence into action - just 12% of supply chain leaders consider themselves AI leaders, despite widespread deployment of AI capabilities. Kinaxis CEO Razat Gaurav and Executive Vice President, EMEA, Fabienne Cêtre, will open the mainstage with an exploration of the market forces reshaping global supply chains and how operational orc
Cebreo Medical Receives CE Mark for NeuroBuds®, a Discreet In-Ear, Medical-Grade EEG Wearable for Extended Ambulatory Monitoring15.9.2026 14:00:00 EEST | Press release
Cebreo Medical today announced that its NeuroBuds® device has received CE marking, confirming conformity with applicable EU requirements. Unlike conventional EEG systems that require a technician-applied cap of electrodes, NeuroBuds is designed to be used unassisted by the patient at home, enabling multi-day and multi-night recordings in a patient's daily life environment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914704547/en/ NeuroBuds(TM), EarEEG “With NeuroBuds, we can offer a discreet, unobtrusive solution that enables long-term, unassisted EEG monitoring for weeks, in patients’ own homes. The product has the potential to significantly reduce the cost of long-term EEG monitoring and strengthen treatment decisions compared with conventional brain monitoring.” — Rasmus Madsen, CEO, Cebreo Medical Designed to resemble a hearing aid, NeuroBuds is built to minimize the stigma and burden that typically limit complianc
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated with TRD, alongside cognitive and emotional patterns, including getting stuck in negative or repetitive ways of thinking, difficulty shifting perspective or navigating emotions, and feeling disconnected from pleasure or motivation1-8. While TRD originates as MDD, its burden and resistance to standard treatments distinguish it as a more complex condition. Compared to MDD, TRD patients experience almost 3x long
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 13:00:00 EEST | Press release
NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these signals to inform where they plan and prioritize media investment. “Marketers shouldn’t have to guess where demand is coming from before they invest,
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 13:00:00 EEST | Press release
QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
